A retrogen plasmid-based vaccine generates high titer antibody responses against the autologous cancer antigen survivin and demonstrates anti-tumor efficacy

Cancer Letters

Volumn 237, Issue 1, 2006, Pages 45-55

  Decker, William K ^a   Qiu, Jianxia ^b   Farhangfar, Farhang ^b   Hester, Jenny H ^b   Altieri, Dario C ^c   Lin, Augustine Y ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MithraGen Inc   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Dendritic cell; DNA vaccine; Survivin

Indexed keywords

CANCER ANTIBODY; DNA VACCINE; PLASMID DNA; RETROGEN PLASMID BASED VACCINE; SURVIVIN; UNCLASSIFIED DRUG; ANTIBODY; CANCER VACCINE; MICROTUBULE ASSOCIATED PROTEIN; SURVIVIN PROTEIN, MOUSE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; FEMALE; IMMUNOGENICITY; INTERMETHOD COMPARISON; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; TH1 CELL; TH2 CELL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CANCER TRANSPLANTATION; COLORECTAL TUMOR; GENETICS; IMMUNOLOGY; METHODOLOGY; VACCINATION;

ANIMALS; ANTIBODIES; ANTIGENS, NEOPLASM; CANCER VACCINES; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; MICE; MICE, INBRED BALB C; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM TRANSPLANTATION; TH1 CELLS; TH2 CELLS; VACCINATION; VACCINES, DNA;

EID: 33746312397     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.05.035     Document Type: Article

References (61)

1. Adida C., Haioun C., Gaulard P., Lepage E., Morel P., Briere J., Dombret H., Reyes F., Diebold J., Gisselbrecht C., Salles G., Altieri D.C., and Molina T.J. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96 (2000) 1921-1925
2. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3 (1997) 917-921
3. Azuhata T., Scott D., Takamizawa S., Wen J., Davidoff A., and Fukuzawa M. Sandler A The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J. Pediatr. Surg. 36 (2001) 1785-1791
4. Balabanian K., Couderc J., Bouchet-Delbos L., Amara A., Berrebi D., Foussat A., Baleux F., Portier A., Durand-Gasselin I., Coffman R.L., Galanaud P., and Peuchmaur M. Emilie D Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J. Immunol. 170 (2003) 3392-3400
5. Basu S., Binder R.J., Ramalingam T., and Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14 (2001) 303-313
6. Bennett B., Check I.J., Olsen M.R., and Hunter R.L. A comparison of commercially available adjuvants for use in research. J. Immunol. Meth. 153 (1992) 31-40
7. Boyle C.M., and Robinson H.L. Basic mechanisms of DNA-raised antibody responses to intramuscular and gene gun immunizations. DNA Cell Biol. 19 (2000) 157-165
8. Bystry R.S., Aluvihare V., Welch K.A., Kallikourdis M., and Betz A.G.B. cells and professional APCs recruit regulatory T cells via CCL4. Nat. Immunol. 2 (2001) 1126-1132
9. Calame K.L. Plasma cells: finding new light at the end of B cell development. Nat. Immunol. 2 (2001) 1103-1108
10. Chakravarti A., Noll E., Black P.M., Finkelstein D.F., Finkelstein D.M., Dyson N.J., and Loeffler J.S. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol. 20 (2002) 1063-1068
11. Chambers R.S., and Johnston S.A. High-level generation of polyclonal antibodies by genetic immunization. Nat. Biotechnol. 21 (2003) 1088-1092
12. Chantalat L.D., Skoufias A., Kleman J.P., Jung B., Dideberg O., and Margolis R.L. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol. Cell 6 (2000) 183-189
13. Deveraux Q.L., and Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev. 13 (1999) 239-252
14. Dhennin-Duthille I., Masson M., Damiens E., Fillebeen C., Spik G., and Mazurier J. Lactoferrin upregulates the expression of CD4 antigen through the stimulation of the mitogen-activated protein kinase in the human lymphoblastic T Jurkat cell line. J. Cell Biochem. 79 (2000) 583-593
15. Fortugno P., Wall N.R., Giodini A., O'Connor D.S., Plescia J., Padgett K.M., Tognin S., Marchisio P.C., and Altieri D.C. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J. Cell. Sci. 115 (2002) 575-585
16. Goldenberg M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21 (1999) 309-318
17. Haggqvist B. Hultman P Effects of deviating the Th2-response in murine mercury-induced autoimmunity towards a Th-1 response. Clin. Exp. Immunol. 134 (2003) 202-209
18. Hauser H., and Chen S.Y. Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods 31 (2003) 225-231
19. Hauser H., Shen L., Gu Q.L., Krueger S., and Chen S.Y. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther. 11 (2004) 924-932
20. Hochhaus G., Brookman L., Fox H., Johnson C., Matthews J., and Ren S. Deniz Y Pharmacodynamics of omalizumab: implications for optimized dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr. Med. Res. Opin. 19 (2003) 491-498
21. Ikeguchi M. Kaibara N Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer. Int. J. Mol. Med. 8 (2001) 661-666
22. Jiang X., Wilford C., Duensing S., Munger K., and Jones G. Jones D Participation of Survivin in mitotic and apoptotic activities of normal and tumor-derived cells. J. Cell. Biochem. 83 (2001) 342-354
23. Kappler M., Kohler T., Kampf C., Diestelkotter P., Wurl P., Schmitz M., Bartel F., Lautenschlager C., Rieber E.P., Schmidt H., Bache M., and Taubert H. Meye A Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int. J. Cancer 95 (2001) 360-363
24. Kato J., Kuwabara Y., Mitani M., Shinoda N., Sato A., Toyama T., Mitsui A., Nishiwaki T., Moriyama S., and Kudo J. Fujii Y Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer 95 (2001) 92-95
25. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., and Tenjo T. Tanigawa N Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58 (1998) 5071-5074
26. Kim K.M., Shin E.Y., Moon J.H., Heo T.H., Lee J.Y., Chung Y., Lee Y.J., Cho H.M., Shin S.U., and Kang C.Y. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen. Int. J. Cancer 102 (2002) 428-434
27. Kobayashi K., Hatano M., Otaki M., and Ogasawara T. Tokuhisa T Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc. Natl. Acad. Sci. USA 96 (1999) 1457-1462
28. Konno R., Yamakawa H., Utsunomiya H., Ito K., and Sato S. Yajima A Expression of survivin and Bcl-2 in the normal human endometrium. Mol. Hum. Reprod. 6 (2000) 529-534
29. Kuhara T., Iigo M., Itoh T., Ushida Y., Sekine K., Terada N., and Okamura H. Tsuda H Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr. Cancer 38 (2000) 192-199
30. Lehner R., Enomoto T., McGregor J.A., Shroyer L., Haugen B.R., Pugazhenthi U., and Shroyer K.R. Correlation of survivin mRNA detection with histologic diagnosis in normal endometrium and endometrial carcinoma. Acta Obstet. Gynecol. Scand. 81 (2002) 162-167
31. Li F., and Altieri D.C. Transcriptional analysis of human survivin gene expression. Biochem. J. 344 (1999) 305-311
32. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., and Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
33. McKay T.R., Bell S., Tenev T., Stoll V., Lopes R., Lemoine N.R., and McNeish I.A. Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy. Oncogene 22 (2003) 3539-3547
34. McLay J., Leonard E., Petersen S., Shapiro D., Greenspan N.S., and Schreiber J.R. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1. J. Immunol. 168 (2002) 3437-3443
35. Monzo M., Rosell R., Felip E., Astudillo J., Sanchez J.J., Maestre J., Martin C., Font A., and Barnadas A. Abad A A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 17 (1999) 2100-2104
36. Muchmore S.W., Chen J., Jakob C., Zakula D., Matayoshi E.D., Wu W., Zhang H., Li F., Ng S.C., and Altieri D.C. Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol. Cell. 6 (2000) 173-182
37. Nance C.L., and Shearer W.T. SDF_1 regulates HIV-1 gp120-induced changes in CD79b surface expression and Ig production in activated human B cells. Clin. Immunol. 105 (2002) 208-214
38. Olie R.A., Simoes-Wust A.P., Baumann B., Leech S.H., Fabbro D., and Stahel R.A. Zangemeister-Wittke U A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60 (2000) 2805-2809
39. Park M.K., Amichay D., Love P., Wick E., Liao F., Grinberg A., Rabin R.L., Zhang H.H., Gebeyehu S., Wright T.M., Iwasaki A., Weng Y., DeMartino J.A., Elkins K.L., Farber J.M., and The C.X.C. chemokines murine monokine induced by IFN-( (CXC chemokine ligand 9) is made by APCs, targets lymphocytes including activated B cells, and supports antibody responses to a bacterial pathogen in vivo. J. Immunol. 169 (2002) 1433-1443
40. Piro L.D., White C.A., Grillo-Lopez A.J., Janakiraman N., Saven A., Beck T.M., Varns C., Shuey S., Czuczman M., Lynch J.W., and Kolitz J.E. Jain V Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10 (1999) 655-661
41. Ravetch J.V. Fc receptors: rubor redux. Cell 78 (1994) 553-560
42. Regnault A., Lankar D., Lacabanne V., Rodriguez A., Thery C., Rescigno M., Saito T., Verbeek S., Bonnerot C., and Ricciardi-Castagnoli P. Amigorena S Fc gamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189 (1999) 371-380
43. Sallusto F. Lanzavecchia A Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179 (1994) 1109-1118
44. Salvesen G.S., and Duckett C.S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell. Biol. 3 (2002) 401-410
45. Sarela A.I., Macadam R.C., Farmery S.M., Markham A.F., and Guillou P.J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46 (2000) 645-650
46. Satoh K., Kaneko K., Hirota M., Masamune A., and Satoh A. Shimosegawa T Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92 (2001) 271-278
47. Scheerlinck J.P.Y. Genetic adjuvants for DNA vaccines. Vaccine 19 (2001) 2647-2656
48. Seol J.G., Heo D.S., Kim H.K., Yoon J.H., Choi B.I., Lee H.S., Kim N.K., and Kim C.Y. Selective gene expression in hepatic tumor with trans-arterial delivery of DNA/liposome/transferrin complex. In Vivo 14 (2000) 513-517
49. Skoufias D.A., Mollinari C., Lacroix F.B., and Margolis R.L. Human survivin is a kinetochore-associated passenger protein. J. Cell. Biol. 151 (2000) 1575-1582
50. Swana H.S., Grossman D., Anthony J.N., Weiss R.M., and Altieri D.C. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N. Engl. J. Med. 341 (1999) 452-453
51. Tanaka K., Iwamoto S., Gon G., Nohara T., and Iwamoto M. Tanigawa N Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 6 (2000) 127-134
52. Tran J., Master Z., Yu J.L., Rak J., Dumont D.J., and Kerbel R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. USA 99 (2002) 4349-4354
53. Uzonna J.E., Kaushik R.S., Gordon J.R., and Tabel H. Cytokines and antibody responses during Trypanosoma congolense infections in two inbred mouse strains that differ in resistance. Parasite Immunol. 21 (1999) 57-71
54. Varadhachary A., Wolf J.S., Petrak K., O'Malley Jr. B.W., Spadaro M., Curcio C., and Forni G. Pericle F Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int. J. Cancer 111 (2004) 398-403
55. Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., and Noel J.P. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat. Struct. Biol. 7 (2000) 602-608
56. Z. Wang, P.J. Troilo, X. Wang, T.G. Griffiths, S.J. Pacchione, A.B. Barnum, L.B. Harper, C.J. Pauley, Z. Niu, L. Denisova, T.T. Follmer, G. Rizzuto, G. Ciliberto, E. Fattori, N.L. Monica, S. Manam, B.J. Ledwith, Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation, Gene Ther. 11 (2004) 711-721.
57. Wolf J.S., Li D., Taylor R.J., and O'Malley Jr. B.W. Lactoferrin inhibits growth of malignant tumors of the head and neck. ORL J. Otorhinolaryngol. Relat. Spec. 65 (2003) 245-249
58. Wurl P., Kappler M., Meye A., Bartel F., Kohler T., Lautenschlager C., Bache M., and Schmidt H. Taubert H Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet 359 (2002) 943-945
59. You Z., Hester J., Rollins L., Spagnoli G.C., Van der B.P., and Chen S.Y. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. Cancer Res. 61 (2001) 197-205
60. You Z., Huang X.F., Hester J., Rollins L., Rooney C., and Chen S.Y. Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway. J. Immunol. 165 (2000) 4581-4591
61. You Z., Huang X., Hester J., Toh H.C., and Chen S.Y. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. 61 (2001) 3704-3711